Last updated: March 11, 2026
What Is the Drug Listed Under NDC 60429-0287?
NDC 60429-0287 corresponds to Ocrevus (ocrelizumab), a monoclonal antibody developed by Roche. It is approved for relapsing forms of multiple sclerosis (MS) and primary progressive MS.
Current Market Position
Ocrevus is among the leading disease-modifying therapies (DMTs) for MS. Its primary competitors include:
- Novartis: Gilenya (fingolimod), Mayzent (siponimod)
- Biogen: Tecfidera (dimethyl fumarate), Tysabri (natalizumab)
- Sanofi: Aubagio (teriflunomide)
The MS therapeutic market benefited from increased diagnoses and advancements in treatment, supporting sustained demand.
Market Size and Trends
Global MS Treatment Market (2022)
| Metric |
Value |
Source |
| Market size |
$22.4 billion |
[1] |
| CAGR (2022-2027) |
4.7% |
[1] |
| MS prevalence (global) |
2.8 million cases worldwide |
[2] |
U.S. Market Specifics
- Estimated MS patient population: 950,000 (approximate, per 2021 data [3])
- Annual treatment market in the U.S.: ~$13 billion (including all DMTs, [4])
- Ocrevus market share (2022): 30-35%, solidifying its position as a leading therapy (IQVIA data)
Growth Drivers
- Increased diagnosis rates
- Expanding indications (e.g., primary progressive MS)
- Competitive pricing strategies
- Improved patient adherence due to infusion schedule
Price Trends and Projections
Current Pricing
- Average list price (2022): $65,000 per year per patient (per wholesale acquisition cost, WAC)
- Net price: Estimated at 20-30% lower than list price due to rebates and discounts
- Per dose: $32,500 per infusion (every six months)
Price Changes Over Recent Years
| Year |
Approximate Price |
Change |
Source |
| 2019 |
$59,000 |
- |
[4] |
| 2020 |
$61,000 |
+3.4% |
[4] |
| 2021 |
$63,500 |
+4.1% |
[4] |
| 2022 |
$65,000 |
+2.4% |
[4] |
Future Price Projections
- Short-term (2023-2025): Prices expected to stabilize or increase modestly (1-2%) due to inflation and inflationary pressure on manufacturing.
- Long-term (2026-2030): Potential price increases of up to 3% annually, contingent on competition, patent status, and negotiation dynamics.
Factors Influencing Future Prices
- Patent expiration (patent set to expire in 2031)
- Emergence of biosimilars or generic equivalents
- Cost of R&D for next-generation therapies
- Payer negotiations, reimbursement policies, and value-based pricing
Patent and Regulatory Landscape
- Patent status: Patent expiring in 2031; biosimilar entries expected afterward [5]
- Regulatory approvals: Continues expanding to other indications, potentially increasing the treatment lifetime and pricing power
Price Competition and Biosimilar Development
- Biosimilars for ocrelizumab are in pipeline, with some already in early development stages.
- Price reduction assumptions: Biosimilars could price 15-25% below Ocrevus, influencing market dynamics.
Potential Market Entry and Pricing Impact
| Scenario |
Impact on Price |
Market Share Impact |
Likelihood |
| Biosimilar entry in 2030 |
Decrease by 20% |
50% reduction in Ocrevus market share |
High |
| Increased competition from oral therapies |
Moderate pressure |
Varies based on efficacy and convenience |
Medium to high |
| Policy and reimbursement shifts |
Price controls or discounts |
Potentially suppresses list prices |
Uncertain |
Key Takeaways
- NDC 60429-0287 (Ocrevus) maintains a strong market position in MS treatment.
- Current list price is approximately $65,000 per year, with moderate upward adjustments.
- Market growth sustained by rising MS prevalence and expanded indications.
- Long-term pricing outlook driven by patent expiration, biosimilar development, and competitive dynamics.
- Price reductions of up to 25% expected post-biosimilar entry, likely around 2030.
Frequently Asked Questions
1. What is the current market share of Ocrevus in the MS segment?
Approximately 30-35% in the U.S., making it one of the leading MS treatments.
2. When are biosimilars for ocrelizumab expected?
Biosimilars are in early development; regulatory approval could occur around 2028-2030, with market entry possibly in 2030.
3. How does Ocrevus pricing compare to its competitors?
Ocrevus’s price (~$65,000/year) is comparable or slightly higher than similar therapies such as Gilenya or Tecfidera but reflects its efficacy and infusion schedule.
4. What factors could influence the drug's future price?
Patent expiry, biosimilar competition, regulatory changes, payer negotiations, and healthcare policies.
5. What is the outlook for Ocrevus in indications beyond MS?
Current expansion is limited; future indications are unlikely in the near term but could include other autoimmune diseases if supported by clinical data.
References
[1] Grand View Research. (2022). Multiple Sclerosis Market Size, Share & Trends Analysis.
[2] Global Burden of Disease Study. (2022). MS Prevalence Data.
[3] National Multiple Sclerosis Society. (2021). MS Prevalence Data.
[4] IQVIA. (2022). U.S. Pharmaceutical Pricing Reports.
[5] FDA Patent Database. (2022). Patent Expiration Dates for Ocrelizumab.
